Latest Posts:

Sorry, no posts matched your criteria.

Follow Us:

Back To Top

Associate: LEADING NEW OPPORTUNITY DISCOVERY IN THERAPEUTICS

Building ventures that design more effective personalised therapies significantly extending healthy lifespan.

Full time, starting asap, remotely or London-based.

About Deep Science Ventures

Deep Science Ventures (DSV) is a venture creator, combining available scientific knowledge and founder-type scientists into high-impact ventures, to build a future where both humans and the planet thrive.

DSV operates in 4 sectors: Agriculture, Computation, Energy and Pharmaceuticals, tackling the challenges defining those areas by taking a first-principles approach and partnering with leading institutions.

In the pharma team we’re focusing on curative therapeutics. The current rate of therapeutic failure is unsustainable and unnecessary. The reasons are well understood, including poor models and lack of specificity, but often simply put down to “science is hard” or lost in a whirlwind of hype around AI. In reality, the knowledge and toolsets are available, but the failure rate of therapeutics remains unconscionably high. This is due to entrenched biases at every stage, from publishing papers to clinician marketing. We work to a thesis which addresses these constraints.

You can read more about our pharma thesis here.

 

About the role

As an Associate you will work in close partnership with the Associate Director for Pharma, our current or future pharma sector Founders and other Associates, focusing on systemic analysis or “scoping”, as we call it, of opportunity areas (OAs) for new venture development, identifying the sort of technologies and ventures that should exist but don’t.

While your main focus will be on opportunity analysis, you’ll be involved across all core functions of venture development, including recruitment and team building, business development, fundraising and portfolio management to quickly develop a broad understanding of the scope of all activities within the business.

KEY RESPONSIBILITIES

● Research and identify new OAs for building building novel therapeutics ventures;
● Recruit a team of multidisciplinary founder-type scientists and work together on venture creation;
● Drive the venture creation process from idea generation to pre-seed and seed investments;
● Support fundraising and business development efforts for the sector.

 

About you

Key requirements:

● Deep technical understanding in inflammation and/or neurodegenerative diseases and experience in drug development;
● You’ll likely have done a translationally focussed PhD in any of (or similar): cell and gene therapy, drug discovery, synthetic biology, cell engineering, molecular biology, biochemistry and molecular biology;
● Demonstrated interest in commercial / business / VC fields, ideally with <2 years experience working as a Business Analyst (or similar);
● Demonstrated level of achievement, taking own initiative and delivering outcome-oriented projects from start to finish. You make things happen.

Pharma Team

Kerstin: Previously led research commercialisation at the UK Government’s flagship initiative for Cell & Gene Therapy where she worked with every major academic life sciences department in the UK. Also held a major role at LifeArc (formerly MRCT), the charity responsible for supporting breakthrough drugs Keytruda ($40bn+ p.a.), Entyvio, Actemra and Tysabri to market. 

Laura: 15 years of strategic partnership experience at one of the worlds largest funders of research, driven £20m+ R&D funding deals with industry and research funders, extensive track record in licensing and spin out formation. PhD in insulin signalling and research experience in academia and industry.

Anis: Immunology researcher at UCB, New therapeutic concepts (oncology) researcher at Boehringer Ingelheim, QA at Lonza on GMP and FDA readiness, PhD candidate in single-cell RNA seq for breast cancer at Oxford.

Kerstin: Previously led research commercialisation at the UK Government’s flagship initiative for Cell & Gene Therapy where she worked with every major academic life sciences department in the UK. Also held a major role at LifeArc (formerly MRCT), the charity responsible for supporting breakthrough drugs Keytruda ($40bn+ p.a.), Entyvio, Actemra and Tysabri to market. 

Laura: 15 years of strategic partnership experience at one of the worlds largest funders of research, driven £20m+ R&D funding deals with industry and research funders, extensive track record in licensing and spin out formation. PhD in insulin signalling and research experience in academia and industry.

Anis: Immunology researcher at UCB, New therapeutic concepts (oncology) researcher at Boehringer Ingelheim, QA at Lonza on GMP and FDA readiness, PhD candidate in single-cell RNA seq for breast cancer at Oxford.

Rosie: Fellow in Therapeutics at Deep Science Ventures and recent MRes graduate in Molecular and Cellular Biosciences from Imperial College London. Achieved a first class honours degree in Biomedical Sciences from Newcastle University in 2020. Committed and passionate about applying their specialised knowledge and hard-working attitude to future bioscience research. Consistent and enthusiastic individual who enjoys working with others and is excited to expand their capabilities.

Rosie: Fellow in Therapeutics at Deep Science Ventures and recent MRes graduate in Molecular and Cellular Biosciences from Imperial College London. Achieved a first class honours degree in Biomedical Sciences from Newcastle University in 2020. Committed and passionate about applying their specialised knowledge and hard-working attitude to future bioscience research. Consistent and enthusiastic individual who enjoys working with others and is excited to expand their capabilities.

 

 

Contact

For further info and to discuss the role, please submit an application via this link here.